These drugs are being tested in clinical trials in MSA patients to determine if they can be proven to alleviate symptoms of neurogenic orthostatic hypotension (nOH) or low blood pressure when standing.
September 15, 2021: Theravance Biopharma, Inc. announces top-line results from a Phase 3 study of Ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension
November 6, 2020: Effect of the Initial Maintenance Dose of Droxidopa on Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension
July 1, 2019: Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)
Click on each drug to learn more details, including links to clinical trial opportunities.
DROXIDOPA (Northera) - FDA Approved 2014
Droxidopa was approved by the FDA in the USA in 2014 and is now sold under the brand name Northera. Although the drug may now be prescribed to MSA patients, additional Phase 4 clinical trials are currently underway to measure its long-term effects.
Droxidopa is intended to treat the symptom neurogenic orthostatic hypotension (low blood pressure when standing) that 80% of MSA patients suffer from.
Clinical Trial Details:
A Phase 4 clinical trial in patients with neurogenic orthostatic hypotension (nOH) is underway.
For Phase 4 clinical trial details See: https://clinicaltrials.gov/ct2/show/NCT02586623
For historical Phase 3 clinical trial details See: https://clinicaltrials.gov/ct2/show/NCT01132326
Related Posters:
November 2020: Effect of the Initial Maintenance Dose of Droxidopa on Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension
Related Videos:
October 2014: VIDEO: Novel Therapeutic Approaches in MSA and Drug Trial Updates
Related Articles:
September 29, 2021: Lupin Launches Droxidopa Capsules in the United States
June 2017: Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
September 2014: How can patients obtain Northera (droxidopa)?
September 2014: Lundbeck’s Northera Now Available Through Specialty Pharmacy
NOTE: All of the above information is intended to assist MSA patients and their families in having a conversation with doctors, none of it should be considered medical advice or endorsements of any particular drugs or therapies. Always consult a licensed medical practitioner for expert care.
AMPRELOXETINE (TD-9855) - Phase 3 Clinical Trial Completed 2021
Ampreloxetine is a novel norepinephrine and serotonin reuptake inhibitor intended to treat the symptom “neurogenic orthostatic hypotension” or NOH (low blood pressure when standing) that 80% of MSA patients suffer from.
Clinical Trial Details:
For historical Phase 3 clinical trial details See: https://clinicaltrials.gov/ct2/show/NCT03750552
For historical Phase 2 clinical trial details See: https://clinicaltrials.gov/ct2/show/NCT02705755
Related Articles:
April 2017: Two New Studies Open for Patients with MSA
December 2014: Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor
NOTE: All of the above information is intended to assist MSA patients and their families in having a conversation with doctors, none of it should be considered medical advice or endorsements of any particular drugs or therapies. Always consult a licensed medical practitioner for expert care.
ATOMEXETINE (Strattera) - Phase 2 Clinical Trial Completed 2021
Sold under the brand name Strattera, Atomexetine is a norepinephrine (noradrenaline) reuptake inhibitor approved for the treatment of attention deficit hyperactivity disorder (ADHD). The Phase 2 clinical trial aims to evaluate the compound as a potential treatment of the symptom neurogenic orthostatic hypotension (low blood pressure when standing) that 80% of MSA patients suffer from.
Clinical Trial Details:
For historical Phase 2 clinical trial details See: https://clinicaltrials.gov/ct2/show/NCT02796209
Related Articles:
March 2018: Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults
October 2017: VIDEO: Treatment of Neurogenic Orthostatic Hypotension in MSA – A New Study
April 2017: Two New Studies Open for Patients with MSA
September 2014: Efficacy of Atomoxetine Versus Midodrine for the Treatment of Orthostatic Hypotension in Autonomic Failure
NOTE: All of the above information is intended to assist MSA patients and their families in having a conversation with doctors, none of it should be considered medical advice or endorsements of any particular drugs or therapies. Always consult a licensed medical practitioner for expert care.
CERC-301 - Phase 1 Clinical Trial Completed 2019
CERC-301 is a selective NR2B specific NMDA receptor antagonist being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson’s Disease, Multiple System Atrophy and Pure Autonomic Failure.
Clinical Trial Details:
For historical Phase 1 clinical trial details See: CERC-301 publications
Related Articles:
NOTE: All of the above information is intended to assist MSA patients and their families in having a conversation with doctors, none of it should be considered medical advice or endorsements of any particular drugs or therapies. Always consult a licensed medical practitioner for expert care.
Efficacy of NOH Treatments - Clinical Study in Progress *
Clinical Trial Details:
The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses).
For clinical trial details See: https://www.clinicaltrials.gov/ct2/show/NCT04782830
Related Articles:
NOTE: All of the above information is intended to assist MSA patients and their families in having a conversation with doctors, none of it should be considered medical advice or endorsements of any particular drugs or therapies. Always consult a licensed medical practitioner for expert care.
More MSA Treatment Pipeline Categories
CLINICAL TRIALS & STUDIES
EXPERIMENTAL LAB WORK
Please be sure to check back regularly to find out what’s new in the Multiple System Atrophy Treatment Pipeline and be sure to Sign up for our newsletter mailing list to stay informed of the latest updates.
Not sure what to look for in a clinical trial? Watch this informative video: Helping you understand clinical trials
Are you interested in participating in a clinical trial? Visit www.clinicaltrials.gov, enter the name of the disease and you’ll be able to stay abreast of the latest clinical trial news. You can also enroll in the Fox Trial Finder which not only allows you to share your information for future research studies but will also inform you of any research study or clinical trial for which you qualify.
© Copyright The Multiple System Atrophy Coalition 1989-2021. All Rights Reserved.